Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children

被引:225
作者
Handgretinger, R
Klingebiel, T
Lang, P
Schumm, M
Neu, S
Geiselhart, A
Bader, P
Schlegel, PG
Greil, J
Stachel, D
Herzog, RJ
Niethammer, D
机构
[1] Univ Tubingen, Dept Pediat Hematol Oncol, Tubingen, Germany
[2] Univ Tubingen, Blood Bank, Tubingen, Germany
[3] Von Haunersches Kinderspital, Munich, Germany
[4] Univ Erlangen Nurnberg, Childrens Univ Hosp, Erlangen, Germany
关键词
mismatch transplantation; CD34-positive selection; donor lymphocyte infusion;
D O I
10.1038/sj.bmt.1702996
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We performed HLA-mismatched stem cell transplantation with megadoses of purified positively selected mobilized peripheral blood CD34(+) progenitor cells (PBPC) from related adult donors in 39 children lacking an otherwise suitable donor. The patients received a mean number of 20.7 +/- 9.8 x 10(6)/kg purified CD34(+) and a mean number of 15.5 +/- 20.4 x 10(3)/kg CD3(+) T lymphocytes. The first seven patients received short term (<4 weeks) GVHD prophylaxis with cyclosporin A, whereas in all the following 32 patients no GVHD prophylaxis was used. In 38 evaluable patients, five patients experienced primary acute GVHD grade I and one patient grade II. In 32 patients, no signs of primary GVHD were seen and GVHD only occurred after T cell add backs. T cell reconstitution was more rapid if the number of transplanted CD34(+) cells exceeded 20 x 10(6)/kg. Of the 39 patients, 15 are alive and well, 13 died due to relapse and 10 transplant-related deaths occurred. We conclude that the HLA barrier can be overcome by transplantation of megadoses of highly purified mismatched CD34(+) stem cells. GVHD can be prevented without pharmacological immunosuppression by the efficient T cell depletion associated with the CD34(+) positive selection procedure. This approach offers a promising therapeutic option for every child without an otherwise suitable donor.
引用
收藏
页码:777 / 783
页数:7
相关论文
共 28 条
  • [1] ANASETTI C, 1995, ANNU REV MED, V46, P169
  • [2] BONE-MARROW TRANSPLANTATION
    ARMITAGE, JO
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) : 827 - 838
  • [3] SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM
    AVERSA, F
    TABILIO, A
    TERENZI, A
    VELARDI, A
    FALZETTI, F
    GIANNONI, C
    IACUCCI, R
    ZEI, T
    MARTELLI, MP
    GAMBELUNGHE, C
    ROSSETTI, M
    CAPUTO, P
    LATINI, P
    ARISTEI, C
    RAYMONDI, C
    REISNER, Y
    MARTELLI, MF
    [J]. BLOOD, 1994, 84 (11) : 3948 - 3955
  • [4] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
    Aversa, F
    Tabilio, A
    Velardi, A
    Cunningham, I
    Terenzi, A
    Falzetti, F
    Ruggeri, L
    Barbabietola, G
    Aristei, C
    Latini, P
    Reisner, Y
    Martelli, MF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) : 1186 - 1193
  • [5] Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT
    Bader, P
    Beck, J
    Frey, A
    Schlegel, PG
    Hebarth, H
    Handgretinger, R
    Einsele, H
    Niemeyer, C
    Benda, N
    Faul, C
    Kanz, L
    Niethammer, D
    Klingebiel, T
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (05) : 487 - 495
  • [6] IMPACT OF RACIAL GENETIC-POLYMORPHISM ON THE PROBABILITY OF FINDING AN HLA-MATCHED DONOR
    BEATTY, PG
    MORI, M
    MILFORD, E
    [J]. TRANSPLANTATION, 1995, 60 (08) : 778 - 783
  • [7] Interleukin 2 in the treatment of acute leukemia
    Blaise, D
    Maraninchi, D
    [J]. LEUKEMIA RESEARCH, 1998, 22 (12) : 1165 - 1170
  • [8] Caron PC, 1998, CLIN CANCER RES, V4, P1421
  • [9] GALE RP, 1986, LANCET, V1, P1468
  • [10] GEISELHART A, 1996, NAT IMMUN, V15, P227